Atlas Molecular Pharma closes a €3 million funding round led by Inveready to advance its clinical program in rare diseases

by Inveready

Atlas Molecular Pharma (Atlas), a biotechnology company and spin-off of CIC bioGUNE, has closed a €3 million investment round aimed at driving the clinical development of ATL-001, its oral clinical-...

Read more

New drug discovery company in the area of rare diseases

by CIC bioGUNE

The new company, Atlas Molecular Pharma, aims to develop a technology capable of detecting molecules which stabilize proteins involved in the development of certain rare diseases. The venture capital ...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Rethinking Alzheimer’s clinical trials...

by Fundació Clínic per a la Recerca Biomèdica

A paper published in Alzheimer’s & Dementia: The Journal of the Alzh...

Photos Stream